BR9914097A - Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto - Google Patents

Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto

Info

Publication number
BR9914097A
BR9914097A BR9914097-7A BR9914097A BR9914097A BR 9914097 A BR9914097 A BR 9914097A BR 9914097 A BR9914097 A BR 9914097A BR 9914097 A BR9914097 A BR 9914097A
Authority
BR
Brazil
Prior art keywords
compound
treatment
viral infection
preparing
pharmaceutical composition
Prior art date
Application number
BR9914097-7A
Other languages
English (en)
Inventor
Christopher Mcguigan
Jan Balzarini
Original Assignee
Univ Cardiff
Rega Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Rega Foundation filed Critical Univ Cardiff
Publication of BR9914097A publication Critical patent/BR9914097A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA E MéTODO DE PROFILAXIA OU TRATAMENTO DE UMA INFECçãO VIRAL E PROCESSO PARA PREPARAçãO DO COMPOSTO". Composto químico compreendendo fosforamidatos nucleosídeo, sua preparação e sua utilização terapêutica no tratamento de infecção viral, especialmente HIV e HBV são divulgadas. Os compostos contêm uma fração de análogo de adenina substituído compreendendo 2-amino-6-(ciclopropilamino)-9H-purin-9-il. Os compostos demonstram ambas atividade antiviral e estabilidade ácida. Sais e ésteres da fosforamidatos são incluídos. Um composto representativo é (1S, 4R), -4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-meta nol-5'-[fenil-(metoxi-L-alaninila)]-fosforamidato.
BR9914097-7A 1998-09-28 1999-09-27 Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto BR9914097A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9821058.6A GB9821058D0 (en) 1998-09-28 1998-09-28 Chemical compound
PCT/GB1999/003207 WO2000018775A1 (en) 1998-09-28 1999-09-27 Antiviral purine derivatives

Publications (1)

Publication Number Publication Date
BR9914097A true BR9914097A (pt) 2001-07-31

Family

ID=10839578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914097-7A BR9914097A (pt) 1998-09-28 1999-09-27 Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto

Country Status (32)

Country Link
US (1) US6638919B2 (pt)
EP (1) EP1117669B1 (pt)
JP (1) JP2002525374A (pt)
KR (1) KR20010085855A (pt)
CN (1) CN1328565A (pt)
AR (1) AR042368A1 (pt)
AT (1) ATE231874T1 (pt)
AU (1) AU762757B2 (pt)
BR (1) BR9914097A (pt)
CA (1) CA2345672A1 (pt)
DE (1) DE69905181T2 (pt)
DK (1) DK1117669T3 (pt)
ES (1) ES2192081T3 (pt)
GB (1) GB9821058D0 (pt)
GC (1) GC0000174A (pt)
GT (1) GT199900166A (pt)
HK (1) HK1036455A1 (pt)
HU (1) HUP0103641A3 (pt)
IL (1) IL141959A0 (pt)
MA (1) MA26694A1 (pt)
MY (1) MY121839A (pt)
NO (1) NO20011198L (pt)
NZ (1) NZ510506A (pt)
PA (1) PA8483101A1 (pt)
PE (1) PE20001072A1 (pt)
PL (1) PL346905A1 (pt)
PT (1) PT1117669E (pt)
TN (1) TNSN99183A1 (pt)
TR (1) TR200100864T2 (pt)
TW (1) TWI243176B (pt)
WO (1) WO2000018775A1 (pt)
ZA (1) ZA200102170B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144647A0 (en) * 1999-02-12 2002-05-23 Glaxo Group Ltd Phosphoramidate, and mono-, di-, and tri-phosphate esters of (ir, cis)-4-(6-amino-9h-purin-9-yl) 2-cyclopentene-1-methanol as antiviral agents
MXPA02000762A (es) 1999-07-22 2002-08-20 Newbiotics Inc Metodos para tratar tumores resistentes a terapia.
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
AU2576001A (en) * 1999-12-10 2001-06-18 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
NZ536942A (en) 2000-07-21 2006-03-31 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20030158532A1 (en) 2002-02-20 2003-08-21 Magee Luke R. Disposable absorbent article designed to facilitate an easy intuitive change
US8716548B2 (en) 2002-02-20 2014-05-06 The Procter & Gamble Company Disposable absorbent article designed to facilitate an easy change
CA2499253A1 (en) 2002-09-30 2004-04-08 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
EP1773355B1 (en) * 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
MXPA06015112A (es) * 2004-06-30 2007-02-08 Lilly Co Eli D-tartrato de 1-(indol-6-carbonil-d-fenilglicinil)-4-(1-metilpiperidin-4-il) piperazina.
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
PL217694B1 (pl) 2010-10-19 2014-08-29 Inst Chemii Bioorg Polskiej Akademii Nauk Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
CN107641121B (zh) * 2016-07-20 2021-02-19 上海高驰资产管理有限公司 一种荧光探针及其制备方法和用途
CN109843900A (zh) * 2016-08-19 2019-06-04 桑多斯股份公司 治疗丙型肝炎的索非布韦衍生物
RU2659388C1 (ru) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN112512529A (zh) * 2018-07-27 2021-03-16 富士胶片株式会社 环戊烯嘌呤衍生物或其盐

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227104A (en) 1987-11-30 1991-11-26 Beecham Group Plc Phosphorus-substituted purine derivatives and pharmaceutical compositions
CA2001715C (en) * 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0468119A1 (en) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
DE69435319D1 (de) 1993-09-17 2010-12-16 Gilead Sciences Inc Nukleotidanaloge
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof

Also Published As

Publication number Publication date
CA2345672A1 (en) 2000-04-06
JP2002525374A (ja) 2002-08-13
TR200100864T2 (tr) 2001-07-23
DK1117669T3 (da) 2003-05-26
AR042368A1 (es) 2005-06-22
PT1117669E (pt) 2003-06-30
GB9821058D0 (en) 1998-11-18
DE69905181D1 (de) 2003-03-06
ZA200102170B (en) 2002-03-15
EP1117669A1 (en) 2001-07-25
US6638919B2 (en) 2003-10-28
EP1117669B1 (en) 2003-01-29
MY121839A (en) 2006-02-28
HUP0103641A3 (en) 2002-10-28
IL141959A0 (en) 2002-03-10
HUP0103641A2 (hu) 2002-04-29
TNSN99183A1 (fr) 2005-11-10
KR20010085855A (ko) 2001-09-07
PA8483101A1 (es) 2000-09-29
NZ510506A (en) 2003-08-29
NO20011198L (no) 2001-05-28
TWI243176B (en) 2005-11-11
PL346905A1 (en) 2002-03-11
MA26694A1 (fr) 2004-12-20
PE20001072A1 (es) 2000-11-20
AU6213899A (en) 2000-04-17
GC0000174A (en) 2006-03-29
CN1328565A (zh) 2001-12-26
WO2000018775A1 (en) 2000-04-06
ATE231874T1 (de) 2003-02-15
NO20011198D0 (no) 2001-03-08
GT199900166A (es) 2001-03-21
AU762757B2 (en) 2003-07-03
HK1036455A1 (en) 2002-01-04
ES2192081T3 (es) 2003-09-16
DE69905181T2 (de) 2003-06-26
US20010031745A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
BR9914097A (pt) Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto
ATE123285T1 (de) Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.
MY103760A (en) Therapeutic nucleosides
EP0786458A3 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
EP0349242A3 (en) Therapeutic nucleosides
AU644095B2 (en) Antiviral compounds
MY104575A (en) Therapeutic nucleosides.
DE3689976T2 (de) Therapeutische Nucleoside und deren Herstellung.
WO1993017020A3 (en) Therapeutic nucleosides
ES2065914T3 (es) Nucleosidos terapeuticos.
ATE74603T1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
KR870006900A (ko) 항바이러스 조성물
BR9508629A (pt) Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica
MY105855A (en) Therapeutic nucleotides.
IL90959A0 (en) Guanine derivatives,their preparation and pharmaceutical compositions containing them
ECSP993155A (es) Compuestos quimicos
EP0317728A3 (en) Use of 9-(beta-d-arabinofuranosyl) adenine derivatives for the preparation of pharmaceutical compositions for the treatment of aids
FI943295A (fi) Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit
MX9709788A (es) Analogos de nucleotidos para tratamiento topico de enfermedades proliferativas de la piel.
GEP19970908B (en) Esters of 9-(2-hydroxyethoxymethyl)guanine having antiviral properties

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050101630/RJ DE 21/09/2005.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1947 DE 29 -- 04 - 2008.